CHMP Recommends Standard Marketing Authorisation for COVID-19 Vaccine Vaxzevria from AstraZeneca

Source: Paul McManus/Pixabay.com

On 13 October 2022 the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) recommended that the conditional marketing authorisation for the vector vaccine Vaxzevria from the company AstraZeneca be converted into a standard marketing authorisation. The EU Commission followed this recommendation on 31 October 2022. A standard marketing authorisation no longer needs to be renewed annually. All other obligations for the pharmaceutical company remain in place.